Clinical trials are an essential component of drug development for new cancer treatments, yet the information required to determine a patient’s eligibility for enrollment is scattered in large amounts of unstructured text. Genomic biomarkers…
Continue ReadingTag: Genomic Biomarkers
Protai Adds $12 Million to Seed Round – Bringing the Total to $20 Million – to Build an Oncology Drug Discovery Pipeline
Since its initial funding last year, Protai has launched collaborations with leading hospitals, opened a wet lab and expanded its advisory board with world-renowned oncology experts, including MD Anderson’s CSO, Prof. Giulio Draetta
Protai, a…